Epic Allies HIV ART Adherence Intervention
Status: | Completed |
---|---|
Conditions: | HIV / AIDS |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 16 - 24 |
Updated: | 1/20/2018 |
Start Date: | June 2015 |
End Date: | December 14, 2017 |
Epic Allies: A Gaming Mobile Phone Application to Improve Engagement in Care, Antiretroviral Uptake, and Adherence Among Young Men Who Have Sex With Men (YMSM) and Trans Women Who Have Sex With Men
This is a two-arm, randomized-controlled trial (RCT) that will test the acceptability,
impact, and long-term sustainability of the Epic Allies intervention application (app), a
theory-based mobile app that utilizes game mechanics and social networking features to
improve engagement in care, antiretroviral therapy (ART) uptake, ART adherence, and viral
suppression among HIV-positive young men who have sex with men (YMSM) and trans women who
have sex with men. Subjects will be randomized to either the intervention branch of the Epic
Allies app or the control branch of the app.
impact, and long-term sustainability of the Epic Allies intervention application (app), a
theory-based mobile app that utilizes game mechanics and social networking features to
improve engagement in care, antiretroviral therapy (ART) uptake, ART adherence, and viral
suppression among HIV-positive young men who have sex with men (YMSM) and trans women who
have sex with men. Subjects will be randomized to either the intervention branch of the Epic
Allies app or the control branch of the app.
Implementation of effective interventions for HIV care engagement is necessary to raise the
percentage of people living with HIV/Acquired Immunodeficiency Syndrome (AIDS) who are
virally suppressed and in continuous care. The ultimate goal of this study is to assess the
effectiveness of a mobile phone app that utilizes game mechanics and social networking
features to improve engagement in care, and ART uptake and adherence among HIV-positive YMSM
and trans women who have sex with men. The high mobile phone ownership among adolescent and
young adults supports using intervention tools based in these familiar available
technologies. If successful, Epic Allies would be clinically attractive, as adherent patients
would require less frequent clinic visits and experience fewer HIV-related secondary
infections and financially attractive, as reducing clinic visits and secondary infections.
Epic Allies could also greatly impact public health as ART adherence reduces HIV infectivity
and subsequently reduces HIV transmission.
This is a two-arm randomized-controlled trial (RCT). All subjects will be randomized either
to the intervention arm and receive the Epic Allies intervention branch of the app or to the
control arm and receive the phone-based notifications only control branch of the app.
Randomization will occur in a 1:1 ratio within each of the two groups (new-to-care and
ART-non-adherent) separately, with an equal number of subjects in the intervention and
control arms. During the 26-week intervention phase, intervention arm subjects will receive
the daily adherence reminders they set up through Epic Allies with tailored feedback for
encouragement and reinforcement. Intervention arm subjects will have 24-hour access to all
features of Epic Allies. The control arm subjects will receive weekly phone-based
notifications to encourage them to view educational information presented in the app.
Subjects will attend study visits at Week 13 (during intervention phase), Week 26 (end of
intervention phase), and Week 39 (post-intervention phase). In-depth qualitative app
satisfaction interviews with a subset of intervention arm subjects will also be conducted to
evaluate acceptability of the app and its potential to improve engagement in care, uptake of
ART, and ART adherence. Outcome measures will include engagement in care, ART uptake, ART
adherence, viral load (VL) change, and VL suppression. The in-depth qualitative app
satisfaction interview will assess intervention impact, acceptability, and long-term
sustainability.
percentage of people living with HIV/Acquired Immunodeficiency Syndrome (AIDS) who are
virally suppressed and in continuous care. The ultimate goal of this study is to assess the
effectiveness of a mobile phone app that utilizes game mechanics and social networking
features to improve engagement in care, and ART uptake and adherence among HIV-positive YMSM
and trans women who have sex with men. The high mobile phone ownership among adolescent and
young adults supports using intervention tools based in these familiar available
technologies. If successful, Epic Allies would be clinically attractive, as adherent patients
would require less frequent clinic visits and experience fewer HIV-related secondary
infections and financially attractive, as reducing clinic visits and secondary infections.
Epic Allies could also greatly impact public health as ART adherence reduces HIV infectivity
and subsequently reduces HIV transmission.
This is a two-arm randomized-controlled trial (RCT). All subjects will be randomized either
to the intervention arm and receive the Epic Allies intervention branch of the app or to the
control arm and receive the phone-based notifications only control branch of the app.
Randomization will occur in a 1:1 ratio within each of the two groups (new-to-care and
ART-non-adherent) separately, with an equal number of subjects in the intervention and
control arms. During the 26-week intervention phase, intervention arm subjects will receive
the daily adherence reminders they set up through Epic Allies with tailored feedback for
encouragement and reinforcement. Intervention arm subjects will have 24-hour access to all
features of Epic Allies. The control arm subjects will receive weekly phone-based
notifications to encourage them to view educational information presented in the app.
Subjects will attend study visits at Week 13 (during intervention phase), Week 26 (end of
intervention phase), and Week 39 (post-intervention phase). In-depth qualitative app
satisfaction interviews with a subset of intervention arm subjects will also be conducted to
evaluate acceptability of the app and its potential to improve engagement in care, uptake of
ART, and ART adherence. Outcome measures will include engagement in care, ART uptake, ART
adherence, viral load (VL) change, and VL suppression. The in-depth qualitative app
satisfaction interview will assess intervention impact, acceptability, and long-term
sustainability.
Inclusion Criteria:
To be considered eligible for enrollment, an individual must meet all the criteria listed
below.
- Ages 16 years and 0 days through 24 years and 364 days, inclusive, at the time of
signed informed consent or assent with parental/legal guardian permission, if
applicable;
- Assigned male sex at birth, is of any gender identity, and self-reports a desire to
engage or is engaging in sex with men;
- Has documentation of a VL collected within the 12 weeks prior to the Baseline visit
that is greater than the LLD for the assay used to test the specimen;
- Be either:
- New-to-care: Newly entered HIV medical care within the 12 months prior to the
Baseline visit; or
- ART-non-adherent: First entered HIV medical care more than 12 months prior to the
Baseline visit;
- Has reliable daily access to an Android- or iOS-based smartphone with a data plan;
- Is able to speak and read English;
- Is willing and able to provide signed informed consent or assent; and
- Parent or legal guardian is willing to provide permission, if applicable.
Exclusion Criteria:
To be considered eligible for enrollment, an individual must not meet any of the criteria
listed below.
- Presence of active serious psychiatric symptoms (e.g., active hallucinations, thought
disorder) that would impair the individual's ability to provide true informed
consent/assent or complete the baseline CAPI survey*;
- Visibly distraught (e.g., suicidal, homicidal, exhibiting violent behavior) at the
time of consent/assent or the baseline CAPI survey*;
- Intoxicated or under the influence of alcohol or other substances to such an extent
that in the opinion of the study staff, the ability to give true informed/assent is
impaired*; or
- At the time of the baseline CAPI survey, intoxicated or under the influence of alcohol
or other substances to such an extent that in the opinion of the study staff, the
subject's ability to understand and answer the questions may be impaired or negatively
impact the integrity of the research data*.
- NOTE: If consent/assent is obtained prior to enrollment and the Baseline visit
date, assessment for these exclusion criteria must be performed again prior to
administration of the baseline CAPI survey. If any are present during the
Baseline visit, the subject cannot be enrolled; do not administer the CAPI
survey. Reassessment of eligibility and enrollment may take place at a later date
per the discretion of the treating clinician.
We found this trial at
5
sites
New Orleans, Louisiana 70112
Principal Investigator: Sue Ellen Abdalian, MD
Phone: 504-988-5348
Click here to add this to my saved trials
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
Click here to add this to my saved trials
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
Click here to add this to my saved trials
4202 E Fowler Ave
Tampa, Florida 33620
Tampa, Florida 33620
(813) 974-2011
Principal Investigator: Patricia Emmanuel, MD
Phone: 813-410-4105
University of South Florida The University of South Florida is a high-impact, global research university...
Click here to add this to my saved trials
Chicago, Illinois 60612
Principal Investigator: Lisa Henry-Reid
Phone: 312-572-4571
Click here to add this to my saved trials